Harmony Biosciences Holdings, Inc.
HRMYNASDAQHealthcare● Active
$32.38
+$0.18(+0.56%)
Market Cap$1.9B
P/E Ratio—
52W High$40.87
52W Low$25.52
Harmony Biosciences Holdings, Inc. (HRMY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HRMY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.87B | $0.71B | $0.58B | $0.44B | $0.31B |
| Cost of Revenue | $0.20B | $0.16B | $0.12B | $0.08B | $0.06B |
| Gross Profit | $0.67B | $0.56B | $0.46B | $0.35B | $0.25B |
| Gross Margin %(computed) | 77.16% | 78.06% | 79.17% | 80.93% | 81.82% |
| Operating Expenses | |||||
| R&D Expenses | $0.19B | $0.15B | $0.08B | $0.07B | $0.03B |
| G&A Expenses | $0.15B | $0.11B | $0.10B | $0.08B | $0.06B |
| Total Operating Expenses | $0.46B | $0.37B | $0.27B | $0.23B | $0.16B |
| Operating Income | $0.21B | $0.19B | $0.19B | $0.12B | $0.09B |
| Operating Margin %(computed) | 24.00% | 26.70% | 32.99% | 27.45% | 28.66% |
| Interest Income | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.02B | $0.02B | $0.02B | $0.02B |
| Income Before Tax | $0.22B | $0.19B | $0.17B | $0.10B | $0.04B |
| Income Tax Expense | $0.06B | $0.05B | $0.04B | ($0.08B) | $0.00B |
| Net Income | $0.16B | $0.15B | $0.13B | $0.18B | $0.03B |
| Net Margin %(computed) | 18.27% | 20.36% | 22.14% | 41.44% | 11.33% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.76 | $2.56 | $2.17 | $3.07 | $0.60 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | $0.26B | $0.23B | $0.22B | $0.15B | $0.08B |
| EBITDA Margin %(computed) | 29.37% | 32.66% | 38.06% | 33.54% | 26.34% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Harmony Biosciences Holdings, Inc. data
About Harmony Biosciences Holdings, Inc. (HRMY) Income Statement
Harmony Biosciences Holdings, Inc. (HRMY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HRMY reported revenue of $0.87B, gross profit of $0.67B (gross margin 77.16%), and net income of $0.16B — a net profit margin of 18.27%.
Frequently asked questions
HRMY · 4 questionsHarmony Biosciences Holdings, Inc. (HRMY) reported revenue of $0.87B for 2025, up 21.5% year-over-year.
HRMY revenueHRMY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08